Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688513'
s Pretax Margin % Range Over the Past 10 Years
Min: 12.24 Med: 20.47 Max: 24.14
Current: 21.05
SHSE:688513's Pretax Margin % is ranked better than 86.61% of 941
companies
in the Biotechnology industry
Industry Median: -89.42
vs SHSE:688513: 21.05
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Chengdu Easton Biopharmaceuticals Co Pretax Margin % Related Terms
Chengdu Easton Biopharmaceuticals Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Pretax Margin % Chart
SHSE:688513 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Pretax Margin % of 14.53% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 29% below median its historical median of 20.47. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Pretax Margin % has ranged from 12.24 to 24.14. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #126 out of 941 companies in the Biotechnology industry, placing it in the top 13.4%.
Is Chengdu Easton Biopharmaceuticals Co's Pretax Margin % too high?
Chengdu Easton Biopharmaceuticals Co's current Pretax Margin % of 14.53% is 29% below median its 10-year median of 20.47. Over the past 10 years, this metric has ranged from a low of 12.24 to a high of 24.14. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #126 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #126 out of 941 companies for Pretax Margin %. This places Chengdu Easton Biopharmaceuticals Co in the top 13% of its industry — outperforming the majority of peers. Historically, Chengdu Easton Biopharmaceuticals Co's own Pretax Margin % has ranged from 12.24 to 24.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Pretax Margin % is 14.53%, which is 29% below median its own 10-year median of 20.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥48.04, compared to a current price of ¥57.55 — trading 19.8% above its estimated fair value. The current Pretax Margin % is 14.53%, which is 29% below median its 10-year median of 20.47. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Pretax Margin % is 14.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥57.55 is trading 19.8% above its estimated GF Value™ of ¥48.04.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SHSE:688513:
Pretax Margin %: 14.53% (29% below median its 10-year median of 20.47)
GF Value™: ¥48.04 vs. price of ¥57.55 (19.8% above fair value)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score
Get the complete analysis for SHSE:688513
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
